FDA moves to waive immunogenicity studies for biosimilar insulin

FDA issued draft guidance on Tuesday that would streamline the approval process for certain biosimilar or interchangeable insulin products by eliminating the need for costly and time-consuming comparative clinical immunogenicity

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE